Rockland Announces General Release of BioQuantiPro™ Host Cell Protein Screening Kit for Bioprocessing
Credit: Rockland
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Rockland Immunochemicals, Inc. announced the general release of their new BioQuantiPro™ CHO-HCP ELISA Kit for detection and screening of host cell protein (HCP) contaminants in bioprocessing. The kit was specifically designed with Rockland’s novel, validated antibodies to detect HCP contaminants and to measure analytes from crude cellular harvests, cell culture lysates, and process intermediates. The BioQuantiPro CHO-HCP ELISA Kit boasts the highest coverage of generic CHO-HCP kits, low variability, and, most importantly, the data to back it all up.
“While working with bioprocessing clients, we consistently hear the same complaint about HCP kits: ‘The generic kit I am using works OK, but I wish I had reliable data that I can trust for the validation of the antibodies used in the kit’” commented Karin Abarca-Heidemann, PhD., Vice President of Science Operations. “We aimed to create a kit that fills the void by providing transparency into the data necessary to develop accurate bioprocessing standards with confidence. We are proud of what we have accomplished with this new kit and look forward to working with customers to advance the science of bioprocessing.”
Rockland has a long history of developing process-specific HCP antibodies in the biotherapeutics field. “Over the last 15 years we have successfully developed and manufactured custom processspecific HCP antibodies for our customers. In the design and function of this CHO-HCP kit, we drew upon our experience gained from working with a diverse set of biopharmaceutical clients. We are eager to see the feedback of the scientists who need this kit,” said David Chimento, PhD., Vice President of Client Solutions.
The BioQuantiPro CHO-HCP ELISA Kit is the first of several bioprocessing kits Rockland expects to release over the next eighteen months. Expect more and get more from Rockland in forthcoming kits for HEK 293 and Escherichia coli expression systems and other common bioprocessing contaminant targets.
“While working with bioprocessing clients, we consistently hear the same complaint about HCP kits: ‘The generic kit I am using works OK, but I wish I had reliable data that I can trust for the validation of the antibodies used in the kit’” commented Karin Abarca-Heidemann, PhD., Vice President of Science Operations. “We aimed to create a kit that fills the void by providing transparency into the data necessary to develop accurate bioprocessing standards with confidence. We are proud of what we have accomplished with this new kit and look forward to working with customers to advance the science of bioprocessing.”
Rockland has a long history of developing process-specific HCP antibodies in the biotherapeutics field. “Over the last 15 years we have successfully developed and manufactured custom processspecific HCP antibodies for our customers. In the design and function of this CHO-HCP kit, we drew upon our experience gained from working with a diverse set of biopharmaceutical clients. We are eager to see the feedback of the scientists who need this kit,” said David Chimento, PhD., Vice President of Client Solutions.
The BioQuantiPro CHO-HCP ELISA Kit is the first of several bioprocessing kits Rockland expects to release over the next eighteen months. Expect more and get more from Rockland in forthcoming kits for HEK 293 and Escherichia coli expression systems and other common bioprocessing contaminant targets.
